Executives
-
Graham Jonathan PEVP & Gen. Counsel & Secy. -
Khosla RachnaSVP, Business Development
-
Busch Matthew C.VP, Finance & CAO
-
Grygiel Nancy A.SVP & CCO
-
Santos EstebanEVP, Operations
-
Reese David MEVP & Chief Technology Officer
-
Miller DerekSVP, Human Resources
-
Griffith Peter H.EVP & CFO
-
Gordon MurdoEVP, Global Commercial Ops
-
Bradner James E.EVP, R&D, & Chief Sci. Officer
?
Khosla Rachna
SVP, Business Development
Amgen Inc.
US, Thousand Oaks [HQ]
CIK
1881332
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
8,597
Price per Share :
$272.11
Equivalence :
$2,339,329.67
Transaction History
-
A8,597 Shares After TransactionValue : $n/a$0.0Transaction Date : 03/06/24
-
Footnotes
-
-
Footnotes:#1 These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 102 RSUs which will vest on 5/5/2024; 252 RSUs which will vest in installments of 124 on 4/30/2024 and 128 on 4/30/2025; 784 RSUs which will vest in installments of 386 on 11/5/2024 and 398 on 11/5/2025; 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#2 These shares include 148 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
-
F8,142 Shares After TransactionValue : $2,250,285.96$13,266.24Transaction Date : 04/30/24
-
Footnotes
-
-
Footnotes:#1 These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 102 RSUs which will vest on 5/5/2024; 128 RSUs which will vest on 4/30/2025; 784 RSUs which will vest in installments of 386 on 11/5/2024 and 398 on 11/5/2025; 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#2 These shares include 157 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
-
F8,068 Shares After TransactionValue : $2,237,821.16$20,525.38Transaction Date : 05/02/24
-
Footnotes
-
-
Footnotes:#1 These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 102 RSUs which will vest on 5/5/2024; 128 RSUs which will vest on 4/30/2025; 784 RSUs which will vest in installments of 386 on 11/5/2024 and 398 on 11/5/2025; 407 RSUs which will vest in installments of 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#2 These shares include 144 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
-
F8,190 Shares After TransactionValue : $2,202,045.30$117,765.06Transaction Date : 03/18/24
-
Footnotes
-
-
Footnotes:#1 These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 102 RSUs which will vest on 5/5/2024; 252 RSUs which will vest in installments of 124 on 4/30/2024 and 128 on 4/30/2025; 784 RSUs which will vest in installments of 386 on 11/5/2024 and 398 on 11/5/2025; 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#2 These shares include 169 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
-
A8,559 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/07/24
-
Footnotes
-
-
Footnotes:#1 The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/7/2026, 5/7/2027 and 5/7/2028, respectively.#2 These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 128 RSUs which will vest on 4/30/2025; 784 RSUs which will vest in installments of 386 on 11/5/2024 and 398 on 11/5/2025; 407 RSUs which will vest in installments of 200 on 5/2/2025, and 207 on 5/2/2026; 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and 202 on 5/2/2027; and 532 RSUs which will vest in installments of 175 on 5/7/2026, 176 on 5/7/2027, and 181 on 5/7/2028. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.#3 These shares include 131 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.